Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ABF-101 in Healthy Participants and AMD Patients
NCT07330674Phase 1Recruiting
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABF-101 in age-related macular degeneration (AMD) (3 arms), sponsored by AptaBio Therapeutics Inc. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events up to 12 weeks. Started Feb 2026; status: recruiting.
02
Drugs
ABF-101
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07330674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330674.